Satsuma Pharmaceuticals, Inc. was delisted on Jun 8, 2023; its insiders filed their last Form 4 on Jun 12, 2023; 31 institutions reported holding it in 13F filings for Q1 2023, worth $12.7M in total; no superinvestor held it.
SEC filings
10-K, 10-Q, 8-K, 20-F and 40-F reports Satsuma Pharmaceuticals, Inc. filed with the SEC, newest first.
Livermore lists each filing's form, 8-K items and dates only. To read a filing, open it on SEC.gov; an 8-K's press release or other attachments, such as exhibit 99.1 for Item 2.02, are in the filing index.
SEC filings by Satsuma Pharmaceuticals, Inc.
Filed
Form
8-K items
Period
Document
Filing index
Jun 8, 2023
8-KCurrent report
1.02Item 1.02: Termination of a material definitive agreement2.01Item 2.01: Completion of an acquisition or disposition of assets3.01Item 3.01: Notice of delisting or failure to meet a listing rule; transfer of listing3.03Item 3.03: Material modification to the rights of security holders5.01Item 5.01: Change in control of the company5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement3.01Item 3.01: Notice of delisting or failure to meet a listing rule; transfer of listing5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements7.01Item 7.01: Regulation FD disclosure9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement3.02Item 3.02: Unregistered sale of equity securities8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits
5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits
